Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02659800 · ClinicalTrials.gov registry record · Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT02659800 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 12 participants.
The verdict
NCT02659800, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and select optimal biological doses (OBD) of the study drug NT-I7 in High Grade Glioma patients with severe lymphopenia, as well as to test the effect of NT-I7 on the CD4 counts of patients in comparison to control participants. This study has both a Phase I and Pilot component.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL NT-I7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02659800
The ClinicalTrials.gov registry entry for NCT02659800 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02659800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02659800 about?
NCT02659800 is a clinical study titled "Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas". The purpose of this study is to determine the maximum tolerated dose (MTD) and select optimal biological doses (OBD) of the study drug NT-I7 in High Grade Glioma patients with severe lymphopenia, as well as to test the effect of NT-I7 on the CD4 counts of patients in comparison to control participan...
What is the current status of trial NCT02659800?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-10-30. Estimated completion is 2023-10-03.
What interventions are being tested in trial NCT02659800?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), NT-I7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02659800?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.